This research study is studying an investigational combination of drugs as a possible treatment for advanced solid tumors: melanoma, ovarian, renal, or colorectal cancer. The drugs involved in this study are: - Pembrolizumab - AMG386
Name: Pembrolizumab
Description: Pembrolizumab is designed to augment the natural ability of the immune system to recognize and target cancer cellsType: DrugPembrolizumab + Trebananib Pembrolizumab + Trebananib (Melanoma) Pembrolizumab + Trebananib (Ovarian) Pembrolizumab + Trebananib (Colorectal) Pembrolizumab + Trebananib (Renal Cell Carcinoma)
Name: Trebananib
Description: AMG386 is a drug that may kill tumor cells and blocks blood vessels that supply the tumor with nutrients and oxygenType: DrugPembrolizumab + Trebananib Pembrolizumab + Trebananib (Melanoma) Pembrolizumab + Trebananib (Ovarian) Pembrolizumab + Trebananib (Colorectal) Pembrolizumab + Trebananib (Renal Cell Carcinoma)
Allocation: Non-Randomized
Parallel Assignment
There are 2 SNPs
Melanoma patients with BRAF V600E or V600K mutation-positive melanoma who have previously received a BRAF inhibitor with or without a MEK inhibitor) are eligible. --- V600E ---
Melanoma patients with BRAF V600E or V600K mutation-positive melanoma who have previously received a BRAF inhibitor with or without a MEK inhibitor) are eligible. --- V600E --- --- V600K ---